This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Results from vaccine trials conducted in the US, South Africa and Brazil found its efficacy against the worst outcomes of the virus was "similarly high" but overall protection was lower in South Africa and Brazil, where virus variants have become dominant.